Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIO-902 in Type 2 Diabetes
NCT00302224Phase 2Completed
- Sponsor
- DiObex, Inc.
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing DIO-902 with Placebo (2 arms). Primary endpoints: Safety and Tolerability at 14 days, Pharmacokinetic Profile at 14 days and 1 more. Started Feb 2005; status: completed.
02
Drugs
levoketoconazole
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00302224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00302224.